The phosphatidylserine targeting antibody bavituximab plus pembrolizumab in unresectable hepatocellular carcinoma : a phase 2 trial
© 2024. The Author(s)..
Immune checkpoint inhibitors targeting PD-1/L1 have modest efficacy in hepatocellular carcinoma as single agents. Targeting membranous phosphatidylserine may induce pro-inflammatory and -immune stimulating effects that enhance immunotherapy activity. This hypothesis was tested in a single-arm phase 2 trial evaluating frontline bavituximab, a phosphatidylserine targeting antibody, plus pembrolizumab (anti-PD-1) in patients with unresectable hepatocellular carcinoma (NCT03519997). The primary endpoint was investigator-assessed objective response rate among evaluable patients, and secondary end points included progression-free survival, incidence of adverse events, overall survival, and duration of response. Among 28 evaluable patients, the confirmed response rate was 32.1%, which met the pre-specified endpoint, and the median progression-free survival was 6.3 months (95% CI, 1.3-11.3 months). Treatment related-adverse events of any grade occurred in 45.7% of patients, with grade 3 or greater adverse events in 14.3% of patients. Adverse events of any cause were observed in 33 patients (94.3%), with grade 3 or greater adverse events in 11 patients (31.4%). Prespecified exploratory analyses of baseline tumor specimens showed that a depletion of B cells, and the presence of fibrotic tissue and expression of immune checkpoints in stroma was associated with tumor response. These results suggest that targeting phosphatidylserine may lead to synergistic effects with PD-1 blockade without increasing toxicity rates, and future studies on this therapeutic strategy may be guided by biomarkers characterizing the pre-treatment tumor microenvironment.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:15 |
|---|---|
| Enthalten in: |
Nature communications - 15(2024), 1 vom: 11. März, Seite 2178 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Hsiehchen, David [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Antibodies, Monoclonal |
|---|
| Anmerkungen: |
Date Completed 13.03.2024 Date Revised 20.03.2024 published: Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1038/s41467-024-46542-y |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM369573676 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM369573676 | ||
| 003 | DE-627 | ||
| 005 | 20240320234702.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240312s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1038/s41467-024-46542-y |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1337.xml |
| 035 | |a (DE-627)NLM369573676 | ||
| 035 | |a (NLM)38467639 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Hsiehchen, David |e verfasserin |4 aut | |
| 245 | 1 | 4 | |a The phosphatidylserine targeting antibody bavituximab plus pembrolizumab in unresectable hepatocellular carcinoma |b a phase 2 trial |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 13.03.2024 | ||
| 500 | |a Date Revised 20.03.2024 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2024. The Author(s). | ||
| 520 | |a Immune checkpoint inhibitors targeting PD-1/L1 have modest efficacy in hepatocellular carcinoma as single agents. Targeting membranous phosphatidylserine may induce pro-inflammatory and -immune stimulating effects that enhance immunotherapy activity. This hypothesis was tested in a single-arm phase 2 trial evaluating frontline bavituximab, a phosphatidylserine targeting antibody, plus pembrolizumab (anti-PD-1) in patients with unresectable hepatocellular carcinoma (NCT03519997). The primary endpoint was investigator-assessed objective response rate among evaluable patients, and secondary end points included progression-free survival, incidence of adverse events, overall survival, and duration of response. Among 28 evaluable patients, the confirmed response rate was 32.1%, which met the pre-specified endpoint, and the median progression-free survival was 6.3 months (95% CI, 1.3-11.3 months). Treatment related-adverse events of any grade occurred in 45.7% of patients, with grade 3 or greater adverse events in 14.3% of patients. Adverse events of any cause were observed in 33 patients (94.3%), with grade 3 or greater adverse events in 11 patients (31.4%). Prespecified exploratory analyses of baseline tumor specimens showed that a depletion of B cells, and the presence of fibrotic tissue and expression of immune checkpoints in stroma was associated with tumor response. These results suggest that targeting phosphatidylserine may lead to synergistic effects with PD-1 blockade without increasing toxicity rates, and future studies on this therapeutic strategy may be guided by biomarkers characterizing the pre-treatment tumor microenvironment | ||
| 650 | 4 | |a Clinical Trial, Phase II | |
| 650 | 4 | |a Journal Article | |
| 650 | 7 | |a pembrolizumab |2 NLM | |
| 650 | 7 | |a DPT0O3T46P |2 NLM | |
| 650 | 7 | |a bavituximab |2 NLM | |
| 650 | 7 | |a Q16CT95N25 |2 NLM | |
| 650 | 7 | |a Phosphatidylserines |2 NLM | |
| 650 | 7 | |a Programmed Cell Death 1 Receptor |2 NLM | |
| 650 | 7 | |a Antibodies, Monoclonal |2 NLM | |
| 650 | 7 | |a Antibodies, Monoclonal, Humanized |2 NLM | |
| 700 | 1 | |a Beg, Muhammad S |e verfasserin |4 aut | |
| 700 | 1 | |a Kainthla, Radhika |e verfasserin |4 aut | |
| 700 | 1 | |a Lohrey, Jay |e verfasserin |4 aut | |
| 700 | 1 | |a Kazmi, Syed M |e verfasserin |4 aut | |
| 700 | 1 | |a Khosama, Leticia |e verfasserin |4 aut | |
| 700 | 1 | |a Maxwell, Mary Claire |e verfasserin |4 aut | |
| 700 | 1 | |a Kline, Heather |e verfasserin |4 aut | |
| 700 | 1 | |a Katz, Courtney |e verfasserin |4 aut | |
| 700 | 1 | |a Hassan, Asim |e verfasserin |4 aut | |
| 700 | 1 | |a Kubota, Naoto |e verfasserin |4 aut | |
| 700 | 1 | |a Siglinsky, Ellen |e verfasserin |4 aut | |
| 700 | 1 | |a Pillai, Anil K |e verfasserin |4 aut | |
| 700 | 1 | |a Youssoufian, Hagop |e verfasserin |4 aut | |
| 700 | 1 | |a Mockbee, Colleen |e verfasserin |4 aut | |
| 700 | 1 | |a Culm, Kerry |e verfasserin |4 aut | |
| 700 | 1 | |a Uhlik, Mark |e verfasserin |4 aut | |
| 700 | 1 | |a Benjamin, Laura |e verfasserin |4 aut | |
| 700 | 1 | |a Brekken, Rolf A |e verfasserin |4 aut | |
| 700 | 1 | |a Ahn, Chul |e verfasserin |4 aut | |
| 700 | 1 | |a Singal, Amit G |e verfasserin |4 aut | |
| 700 | 1 | |a Zhu, Hao |e verfasserin |4 aut | |
| 700 | 1 | |a Hoshida, Yujin |e verfasserin |4 aut | |
| 700 | 1 | |a Yopp, Adam C |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Nature communications |d 2010 |g 15(2024), 1 vom: 11. März, Seite 2178 |w (DE-627)NLM199274525 |x 2041-1723 |7 nnns |
| 773 | 1 | 8 | |g volume:15 |g year:2024 |g number:1 |g day:11 |g month:03 |g pages:2178 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1038/s41467-024-46542-y |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 15 |j 2024 |e 1 |b 11 |c 03 |h 2178 | ||